Contract Pharma Staff10.15.20
GSK and Delpharm have entered into an agreement under which Delpharm will acquire GSK’s Poznań manufacturing facility in Poland. Subject to the appropriate regulatory clearances, the transaction will see the ownership of GSK’s Poznań manufacturing site, including all facilities and around 700 manufacturing employees, transfer over to Delpharm. Delpharm will continue to manufacture, under contract, the existing GSK product line for a minimum of five years, while GSK will remain the owner and marketing authorization holder of these products.
Delpharm, headquartered in France, is a global contract development and manufacturing organization (CDMO). The company has been providing development services for more than 30 years, and serves 120 markets.
“We have a talented and dedicated team whose high standards have ensured that the Poznań manufacturing site has been performing strongly,” said Kamilla Niedzielska, Poznań site director, GSK. “Our priority is to support them through the transition and consult with them along the way, along with Delpharm. In the meantime, we remain wholly committed to maintaining operations and delivering continuity of supply for our patients and consumers.”
Delpharm said it is committed to expanding its worldwide supply and the Poznań manufacturing site, with its competitive cost base, high quality production, continuous improvement mindset and diverse dose forms, has an important role to play.
Sébastien Aguettant, chief executive officer, Delpharm, said, “Further to our existing businesses with GSK Consumer Healthcare and Vaccines, we are delighted to expand our partnership with GSK Phama with the acquisition of the Poznan sites which is our first step in Central and Eastern Europe.”
GSK has been present in Poland for over 40 years, employing over 2,400 people in the country.
Poznań remains a key strategic location for GSK which has hired over 270 people during the past twelve months at its Europe Finance Hub, established in the city in 2019. The Business Service Center in Poznań was set up in 2005 and is the biggest GSK unit in Poland, made up of 700 specialists, both full time and contract workers.
Delpharm, headquartered in France, is a global contract development and manufacturing organization (CDMO). The company has been providing development services for more than 30 years, and serves 120 markets.
“We have a talented and dedicated team whose high standards have ensured that the Poznań manufacturing site has been performing strongly,” said Kamilla Niedzielska, Poznań site director, GSK. “Our priority is to support them through the transition and consult with them along the way, along with Delpharm. In the meantime, we remain wholly committed to maintaining operations and delivering continuity of supply for our patients and consumers.”
Delpharm said it is committed to expanding its worldwide supply and the Poznań manufacturing site, with its competitive cost base, high quality production, continuous improvement mindset and diverse dose forms, has an important role to play.
Sébastien Aguettant, chief executive officer, Delpharm, said, “Further to our existing businesses with GSK Consumer Healthcare and Vaccines, we are delighted to expand our partnership with GSK Phama with the acquisition of the Poznan sites which is our first step in Central and Eastern Europe.”
GSK has been present in Poland for over 40 years, employing over 2,400 people in the country.
Poznań remains a key strategic location for GSK which has hired over 270 people during the past twelve months at its Europe Finance Hub, established in the city in 2019. The Business Service Center in Poznań was set up in 2005 and is the biggest GSK unit in Poland, made up of 700 specialists, both full time and contract workers.
